Healthcare Industry News: ezetimibe/simvastatin
News Release - March 13, 2006
Data Analysis Showed VYTORIN(R) (ezetimibe/simvastatin) Significantly Reduced LDL ''bad'' Cholesterol and C-reactive Protein (CRP) in Patients with High Cholesterol Compared to Zocor(R) (simvastatin)
Source: Merck-Schering Plough
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.